Aliskiren: clinical experience and future perspectives of renin inhibition. Abstract Text:
BACKGROUND: Aliskiren, the first renin inhibitor with sufficient bioavailability for oral use, is now available to clinicians treating hypertension. OBJECTIVE: The novel mechanism by which aliskiren works was used to provide understanding of its therapeutic and adverse effects. METHODS: After reviewing physiology and preclinical studies, human studies of aliskiren in hypertension were reviewed. Effects of aliskiren on serum levels and enzymatic activity of renin were explored. RESULTS/CONCLUSIONS: Aliskiren has antihypertensive efficacy similar to existing medications such as thiazide diuretics, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and can be used in drug combinations. Preclinical studies indicate possible cardioprotective and renoprotective effects, similar to other inhibitors of the renin-angiotensin cascade, but future studies are needed in humans.
Aliskiren: clinical experience and future perspectives of renin inhibition. Publishing Authors By Initials
